AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19567246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16397129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplantation (ASCT) prepared by melphalan 220 mg/m(2) and 160 mg dexamethasone with or without anti-IL-6 monoclonal antibody (IFM99-04 protocol)
Number of subjects: 284
Study 16397129 — intervention group
Group type: COMPARATOR
Intervention: Autologous stem cell transplantation followed by dose-reduced allogeneic stem cell transplantation (IFM99-03 trial)
Number of subjects: 284
Study 16397129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplantation (ASCT)
Number of subjects: 284
Study 15132026 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal walking
Number of subjects: 8
Study 15132026 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking whilst swinging arms at twice the natural frequency
Number of subjects: 8
Study 11709334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg
Number of subjects: 16
Study 11709334 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400 mg
Number of subjects: 16
Study 11709334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 16
Study 11709334 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 16
Study 9160765 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine SRO (IS) 5 mg
Number of subjects: 12
Study 9160765 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril (SP) 6 mg
Number of subjects: 12
Study 9160765 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine plus Spirapril (IS + SP)
Number of subjects: 12
Study 9160765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8425514 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (Glc) ingestion
Number of subjects: 7
Study 8425514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) ingestion
Number of subjects: 7
Study 2965232 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 0
Study 2965232 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II)
Number of subjects: 0
Study 2965232 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP against a nonpressor background infusion of ANG II
Number of subjects: 0
Study 2965232 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP against a background infusion of ANG II
Number of subjects: 0
Study 31526671 — intervention group
Group type: EXPERIMENTAL
Intervention: BMV < 4
Number of subjects: 2092
Study 31526671 — intervention group
Group type: EXPERIMENTAL
Intervention: BMV 4-13
Number of subjects: 2092
Study 31526671 — intervention group
Group type: EXPERIMENTAL
Intervention: BMV > 13
Number of subjects: 2092
Study 31526671 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 2092
Study 31526671 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma histology
Number of subjects: 2092
Study 31526671 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of initial brain metastases
Number of subjects: 2092
Study 29799968 — intervention group
Group type: COMPARATOR
Intervention: Daily sublingual buprenorphine with naloxone (SL-BPN/NX group)
Number of subjects: 428
Study 29799968 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly and monthly subcutaneous buprenorphine (SC-BPN group)
Number of subjects: 428
Study 27355499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives ($5 plus $1 increment at each visit) conditional on attending scheduled clinic visits and accepting PMTCT services.
Number of subjects: 433
Study 27355499 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 433
Study 27355499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives (intervention group).
Number of subjects: 433
Study 24943722 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Number of subjects: 338
Study 24943722 — intervention group
Group type: EXPERIMENTAL
Intervention: atovaquone-proguanil
Number of subjects: 338
Study 24943722 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-atovaquone-proguanil
Number of subjects: 338
Study 23616548 — intervention group
Group type: EXPERIMENTAL
Intervention: High argument strength (AS) ads
Number of subjects: 71
Study 23616548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low argument strength (AS) ads
Number of subjects: 71
Study 23616548 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI activation in the dorsomedial prefrontal cortex (dMPFC)
Number of subjects: 71
Study 23616548 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate recall of ads
Number of subjects: 71
Study 23616548 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate change in intentions to quit smoking
Number of subjects: 71
Study 23616548 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine levels of cotinine at 1 month follow-up
Number of subjects: 71
Study 20494268 — intervention group
Group type: EXPERIMENTAL
Intervention: Molindone
Number of subjects: 54
Study 20494268 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 54
Study 20494268 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 54
Study 20494268 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 54
Study 18375898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus best supportive care (P+BSC)
Number of subjects: 243
Study 18375898 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 243
Study 16337041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (n = 24)
Number of subjects: 45
Study 16337041 — intervention group
Group type: COMPARATOR
Intervention: No statin (Control group, n = 21)
Number of subjects: 45
Study 14602767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 12
Study 14602767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10952950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 42
Study 10952950 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 42
Study 10952950 — intervention group
Group type: COMPARATOR
Intervention: Combination of aspirin and nimesulide
Number of subjects: 42
Study 10952950 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study 10952950 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 42
Study 8793447 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a self-management plan (SM)
Number of subjects: 125
Study 8793447 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a doctor-managed regimen (DM)
Number of subjects: 125
Study 1661247 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically oriented treatment for alcoholism during hospitalization (16 +/- 10 days, 1 to 4 psychotherapeutic interviews)
Number of subjects: 147
Study 1661247 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically oriented treatment for alcoholism
Number of subjects: 147
Study 1661247 — intervention group
Group type: COMPARATOR
Intervention: Post-hospitalization psychotherapeutic program
Number of subjects: 147
Study 1661247 — intervention group
Group type: COMPARATOR
Intervention: Need for medical supervision
Number of subjects: 147
Study 1661247 — intervention group
Group type: COMPARATOR
Intervention: Employment status
Number of subjects: 147
Study 571202 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk with 1.75 g/kg of body weight of lactose
Number of subjects: 14
Study 571202 — intervention group
Group type: COMPARATOR
Intervention: Aqueous lactose solution
Number of subjects: 14
Study 571202 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide with lactulose meal
Number of subjects: 14
Study 31470168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-implant density (HID)
Number of subjects: 0
Study 31470168 — intervention group
Group type: COMPARATOR
Intervention: Low-implant density (LID)
Number of subjects: 0
Study 31467510 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemocoagulase
Number of subjects: 100
Study 31467510 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline (1:1000 dilution)
Number of subjects: 100
Study 28854574 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education And Relationship Training (HEART), a web-based intervention, completed in approximately 45 minutes.
Number of subjects: 222
Study 28854574 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education And Relationship Training (HEART)
Number of subjects: 222
Study 25451017 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone plus risperidone
Number of subjects: 40
Study 25451017 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 40
Study 23788598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (ESRD patients)
Number of subjects: 28
Study 23788598 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 28
Study 23788598 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis (ESRD patients)
Number of subjects: 28
Study 21591523 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 64
Study 21591523 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 64
Study 19133704 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (50-400 mg, once daily for up to 14 days)
Number of subjects: 119
Study 19133704 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (50-400 mg)
Number of subjects: 119
Study 19133704 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 119
Study 16886931 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 50
Study 16886931 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study 16024131 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I therapy (20 microg/kg/day with dose escalation to 50-100 microg/kg/day for 4 months)
Number of subjects: 18
Study 16024131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12538212 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block with bupivacaine (EDA)
Number of subjects: 16
Study 12538212 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (Control)
Number of subjects: 16
Study 10215195 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion through the venous bypass circuit
Number of subjects: 40
Study 10215195 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 7609336 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 22
Study 7609336 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 22
Study 7609336 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 22
Study 2792920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days
Number of subjects: 90
Study 2792920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days
Number of subjects: 90
Study 2792920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks
Number of subjects: 90
Study 2792920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks with IUCD
Number of subjects: 90
Study 2792920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days with IUCD
Number of subjects: 90
Study 2792920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days and IUCD
Number of subjects: 90
Study 292537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation on pylon within 24 hours of surgery
Number of subjects: 24
Study 292537 — intervention group
Group type: COMPARATOR
Intervention: Ambulation at time of suture removal
Number of subjects: 24
Study 292537 — intervention group
Group type: EXPERIMENTAL
Intervention: Casts applied by physical therapists
Number of subjects: 24
Study 292537 — intervention group
Group type: COMPARATOR
Intervention: Casts applied by prosthetists
Number of subjects: 24
Study 292537 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 24
Study 29369680 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention manipulation to losses or gains in Experiment 2
Number of subjects: 0
Study 29369680 — intervention group
Group type: EXPERIMENTAL
Intervention: Predecisional attention allocation to outcome and probability information in Experiment 1
Number of subjects: 0
Study 28592074 — intervention group
Group type: EXPERIMENTAL
Intervention: iASSIST-TKA
Number of subjects: 47
Study 28592074 — intervention group
Group type: COMPARATOR
Intervention: PSI-TKA
Number of subjects: 47
Study 26537937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol intake (up to 2000 mg/d for 12 weeks)
Number of subjects: 80
Study 26537937 — intervention group
Group type: COMPARATOR
Intervention: CF-free control
Number of subjects: 80
Study 22922327 — intervention group
Group type: EXPERIMENTAL
Intervention: 1kHz IFC
Number of subjects: 150
Study 22922327 — intervention group
Group type: EXPERIMENTAL
Intervention: 2kHz IFC
Number of subjects: 150
Study 22922327 — intervention group
Group type: COMPARATOR
Intervention: 8kHz IFC
Number of subjects: 150
Study 22922327 — intervention group
Group type: COMPARATOR
Intervention: 10kHz IFC
Number of subjects: 150
Study 22922327 — intervention group
Group type: COMPARATOR
Intervention: 4kHz IFC
Number of subjects: 150
Study 20049578 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric (OG) tube with suctioning
Number of subjects: 32
Study 20049578 — intervention group
Group type: COMPARATOR
Intervention: No OG tube
Number of subjects: 32
Study 18476432 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianlie Huazhuo Capsule (QHC)
Number of subjects: 65
Study 18476432 — intervention group
Group type: COMPARATOR
Intervention: Qianlie Jiedu Capsule (Control)
Number of subjects: 65
Study 15982658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 481
Study 15982658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 12753271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 98
Study 12753271 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 98
Study 10540069 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol and remifentanil (125 microg of remifentanil added to 500 mg of propofol)
Number of subjects: 71
Study 10540069 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia with sevoflurane and intra-operative alfentanil
Number of subjects: 71
Study 10540069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study 8712091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (10-100 mg orally daily for 12 weeks)
Number of subjects: 16
Study 2032862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminized body covers
Number of subjects: 60
Study 2032862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminized head cover
Number of subjects: 60
Study 2032862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both head and body aluminized covers
Number of subjects: 60
Study 2032862 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no aluminized covers)
Number of subjects: 60
Study 7049311 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal metronidazole twice-daily for 5 days
Number of subjects: 71
Study 7049311 — intervention group
Group type: COMPARATOR
Intervention: No further antibacterial treatment
Number of subjects: 71
Study 31445345 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 30 mg per day
Number of subjects: 50
Study 31445345 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg per day plus placebo
Number of subjects: 50
Study 29911768 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot sciatic nerve block (SNB) with 0.25% bupivacaine 25 ml + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Number of subjects: 78
Study 29911768 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral parecoxib 40 mg q 12 hours + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Number of subjects: 78
Study 29911768 — intervention group
Group type: COMPARATOR
Intervention: Only continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Number of subjects: 78
Study 25982007 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement-Based Treatment (RBT) plus low cost Contingency Management (CM)
Number of subjects: 262
Study 25982007 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement-Based Treatment (RBT)
Number of subjects: 262
Study 24485109 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid (36°C)
Number of subjects: 72
Study 24485109 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature irrigation fluid
Number of subjects: 72
Study 22464778 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming kidney prescription treatment
Number of subjects: 96
Study 22464778 — intervention group
Group type: COMPARATOR
Intervention: Control (telbivudine monotherapy only)
Number of subjects: 96
Study 19427806 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) housing intervention
Number of subjects: 22
Study 17289477 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg/min)
Number of subjects: 120
Study 17289477 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (1 microg/kg for induction, 0.5 microg/kg for skin incision, and then 0.02 microg/kg/min)
Number of subjects: 120
Study 17289477 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120
Study 17289477 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 120
Study 15603013 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM-based multimedia psychoeducational intervention
Number of subjects: 194
Study 15603013 — intervention group
Group type: COMPARATOR
Intervention: Printed material
Number of subjects: 194
Study 11074109 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-night sleep deprivation (LSD)
Number of subjects: 9
Study 11074109 — intervention group
Group type: COMPARATOR
Intervention: Early-night sleep deprivation (ESD)
Number of subjects: 9
Study 11074109 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep after LSD
Number of subjects: 9
Study 11074109 — intervention group
Group type: COMPARATOR
Intervention: Recovery sleep after ESD
Number of subjects: 9
Study 9314933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymotrypsin-galactose pretreatment before IUI
Number of subjects: 26
Study 9314933 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 26
Study 9314933 — intervention group
Group type: COMPARATOR
Intervention: Conventional IUI (Control)
Number of subjects: 26
Study 8338943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX), 1,600 mg/d in four divided doses from day -8 until day +100 post-BMT
Number of subjects: 140
Study 8338943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140
Study 8338943 — intervention group
Group type: COMPARATOR
Intervention: Control (no PTX)
Number of subjects: 140
Study 3520988 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal antibody
Number of subjects: 13
Study 3520988 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with azathioprine and high‐dose steroids
Number of subjects: 13
Study 29284645 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting program focused on reading aloud; included borrowing children's books weekly and monthly parent workshops.
Number of subjects: 566
Study 29284645 — intervention group
Group type: COMPARATOR
Intervention: Standard child care without a parenting component (control).
Number of subjects: 566
Study 27688200 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 128
Study 27688200 — intervention group
Group type: COMPARATOR
Intervention: STN DBS
Number of subjects: 128
Study 24990022 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive knowledge of disabilities (intellectual awareness)
Number of subjects: 34
Study 24990022 — intervention group
Group type: EXPERIMENTAL
Intervention: Online awareness (self-prediction)
Number of subjects: 34
Study 24990022 — intervention group
Group type: EXPERIMENTAL
Intervention: Online awareness (self-assessment)
Number of subjects: 34
Study 21398413 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma patients (NTG)
Number of subjects: 18
Study 21398413 — intervention group
Group type: COMPARATOR
Intervention: Controls without ON or intracranial disease
Number of subjects: 18
Study 20012230 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell therapy
Number of subjects: 20
Study 20012230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18435713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery rehearsal technique
Number of subjects: 64
Study 18435713 — intervention group
Group type: COMPARATOR
Intervention: Textbook study
Number of subjects: 64
Study 16180148 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 41
Study 16180148 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 41
Study 12593055 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique (OT)
Number of subjects: 50
Study 12593055 — intervention group
Group type: COMPARATOR
Intervention: Closed technique (CT)
Number of subjects: 50
Study 10190763 — intervention group
Group type: EXPERIMENTAL
Intervention: Uribenz 300
Number of subjects: 18
Study 10190763 — intervention group
Group type: COMPARATOR
Intervention: Zyloric 300
Number of subjects: 18
Study 7498223 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar thallium-201 perfusion and FDG metabolism imaging
Number of subjects: 27